Human Genome Sciences Announces Required Offer to Repurchase in Respect of Its 3.00% Convertible Senior Notes Due 2018
16:01 EDT 3 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Human Genome Sciences (“HGS”), a wholly owned subsidiary of
GlaxoSmithKline plc (“GSK”), announced today (1) a temporary increase in
the conversion rate applicable to conversions of its 3.00% Convertible
Senior Notes due...
Other Sources for this Article
Human Genome Sciences
Susannah Budington
Director, Corporate
Public Relations
301-545-1062
or
Jerry Parrott
Vice
President, Corporate Communications
301-315-2777
More From BioPortfolio on "Human Genome Sciences Announces Required Offer to Repurchase in Respect of Its 3.00% Convertible Senior Notes Due 2018"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
